Daraxonrasib enters the crowded RAS-mutant NSCLC space with early clinical signal
RAS family mutations appear in an estimated 30% of patients with non-small-cell lung cancer, yet only a minority carry KRAS G12C, the one molecular subtype with approved targeted therapy. For everyone outside that narrow lane, the therapeutic problem has been persistent and familiar: a common oncogenic driver, but few direct drug options. The phase I/II RMC-6236-001 trial now adds a new piece to that picture, with preliminary evidence that the multiselective pan-RAS inhibitor daraxonrasib can produce promising activity in previously treated advanced-stage disease.
A total of 136 patients received daraxonrasib at doses up to 300 mg. These were not treatment-naive patients testing a first-line shortcut; they had already received a median of two previous lines of therapy, excluding any KRAS G12C-targeted agent. The most common molecular subtypes were RASG12V, present in 37% of participants, and RASG12D, present in 30%. Safety served as the primary endpoint, a design choice that fits an early-phase study of a first-in-class or near first-in-class strategy where tolerability must be established before any mature efficacy claims can hold weight.
One sentence in the clinical story stands out more than the rest: this is a population with limited targeted options, and the trial is pushing directly into that gap.
Why pan-RAS inhibition matters in lung cancer
RAS proteins sit near the top of a signaling network that drives cell growth, survival, and proliferation. When these proteins are locked into oncogenic signaling states, downstream pathways remain active even after conventional therapy has failed. In NSCLC, that biology creates an especially stubborn therapeutic barrier because the disease is often already genomically complex by the time patients reach later-line treatment. A multiselective pan-RAS inhibitor is conceptually appealing because it is not confined to one mutation subtype such as KRAS G12C; instead, it is designed to address a broader range of RAS alterations.
That broader reach is the point. In a disease where RAS mutations are common but molecularly fragmented, a drug with activity across multiple RAS variants could matter more than another agent aimed at a single narrow subgroup. The mutation mix in this cohort reinforces that logic. RASG12V and RASG12D are both common enough to be clinically important, yet neither has historically been served by a robust targeted treatment pathway in the way KRAS G12C has.
The early efficacy signal comes in a heavily pretreated cohort
The available data are still early, but the setting makes the signal meaningful. These patients had already moved through a median of two prior lines of therapy, meaning the trial was not sampling an easy-to-treat population with preserved sensitivity to standard regimens. In advanced NSCLC, the later-line setting often carries layered resistance mechanisms, declining performance status, and narrower therapeutic margins. Any agent showing meaningful activity there deserves close attention, especially when it is aimed at a canonical oncogenic driver rather than an indirect downstream vulnerability.
Safety as the primary endpoint also matters because pan-RAS inhibition raises obvious questions about therapeutic window. RAS signaling is central to tumor biology, but it also intersects with normal cellular function across multiple tissues. Early clinical development therefore has to answer a blunt question before any larger efficacy ambitions can be justified: can the pathway be suppressed without unacceptable toxicity? The design of RMC-6236-001 suggests investigators treated that question as foundational, not secondary.
Mutation subtype and drug design are shaping the next phase of precision oncology
The distribution of mutation subtypes in this study hints at where precision oncology may be heading next. For years, targeted therapy in lung cancer has advanced by subdividing tumors into increasingly specific molecular bins. KRAS G12C was the first major RAS-family foothold in that effort, but the majority of RAS-mutant disease still sits outside that specific alteration. A multiselective inhibitor such as daraxonrasib attempts to move beyond that bottleneck and meet the biology where it actually exists in the clinic.
Mechanistically, that approach is attractive because the RAS family functions as a central signaling node rather than a collection of unrelated lesions. Blocking several mutant forms at once may limit the problem of subtype exclusion, though it may also create a more complex safety profile than a mutation-specific drug. Early-phase trials like this one are therefore not just about response; they are about whether the pharmacology is broad enough to be useful and selective enough to be tolerable.
What the trial can and cannot claim yet
For now, the clearest result is that daraxonrasib has shown promising preliminary efficacy in a hard-to-treat population of previously treated RAS-mutant advanced NSCLC. The study enrolled 136 patients, used doses up to 300 mg, and included a molecularly mixed cohort dominated by RASG12V and RASG12D alterations. Those details are enough to show relevance, but not enough to define the drug’s place in treatment sequencing.
What remains unknown is the durability of benefit, how deep responses will prove to be across subgroups, and whether safety remains manageable as exposure continues. The article body does not provide those outcome details, and they should not be inferred. Even so, the clinical direction is hard to miss: a pan-RAS strategy is moving from concept to early patient data in a disease that has long been underserved outside KRAS G12C.
The next question is not whether RAS biology matters in lung cancer. It already does. The real issue is whether a broader inhibitor can translate that biology into a tolerable treatment option for the many patients whose tumors do not fit the narrowest targetable category.